{"entity":{"id":"paper-juarez-ivermectin-repositioned-cancer-drug-2018","kind":"paper","name":"The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","aka":[],"tldr":"A 2018 review that gathered the cell-culture and animal experiments on ivermectin and argued it was ready for cancer trials; those trials began five years later and have not reported.","summary":"The review summarises in vitro and in vivo experiments in which ivermectin acted on multidrug resistance protein, Akt/mTOR and WNT-TCF signalling, purinergic receptors, PAK1, the SIN3A and SIN3B epigenetic regulators, RNA helicase and chloride channels, and on cancer stem-like cells (Juarez review 2018). It argues that the concentrations used are reachable in people on the basis of pharmacokinetic studies in healthy and parasite-infected volunteers, and that this could allow a rapid move into trials (Juarez review 2018).","asOf":"2026-09-24","links":[{"label":"Juarez review 2018","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5835698/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29511601/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["drug-repurposing","fenbendazole-ivermectin-repurposing-claims"],"targets":[],"drugs":["ivermectin"],"companies":[],"institutions":[],"pathways":[],"terms":["in-vitro-in-vivo","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Fable 5.1)","editedOn":"2026-09-24","note":"Written from cached ClinicalTrials.gov v2, Europe PMC, DailyMed, Drugs@FDA and WHO eEML responses; no figure appears without its source link."},"journal":"American Journal of Cancer Research","year":2018,"pmid":"29511601","authors":"Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A.","paperType":"review","findings":["Laboratory evidence only: cell lines and animal models across several cancer types.","Argues that anticancer concentrations are clinically reachable, on pharmacokinetic grounds, not on any patient data."],"whatItMeans":"This is the paper the online claims usually trace back to. It is a call for trials, not evidence that the drug works in people, and the trials it called for are still running.","caveats":["No human efficacy data existed when it was written and none has been published since.","The concentration argument has not been tested in a cancer patient."],"changedPractice":false},"route":"/key-papers/paper-juarez-ivermectin-repositioned-cancer-drug-2018/","neighbours":{"technology":[{"id":"fenbendazole-ivermectin-repurposing-claims","kind":"technology","name":"Fenbendazole, ivermectin and other internet 'repurposed cures'","route":"/technologies/fenbendazole-ivermectin-repurposing-claims/"},{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/"}],"drug":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/"}],"term":[{"id":"in-vitro-in-vivo","kind":"term","name":"In vitro and in vivo","route":"/terms/in-vitro-in-vivo/"},{"id":"preclinical","kind":"term","name":"Preclinical","route":"/terms/preclinical/"}]}}